pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2009-5-120-126pulmo-1591Research ArticleСтатьиИнгаляционный тобрамицин в лечении синегнойной
инфекции у больных муковисцидозомАмелинаЕ. Л.noemail@neicon.ruЧучалинА. Г.noemail@neicon.ruФГУ НИИ пульмонологии ФМБА РоссииRussian Federation20092810200905120126Copyright © Амелина Е.Л., Чучалин А.Г., 20092009Амелина Е.Л., Чучалин А.Г.Амелина Е.Л., Чучалин А.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1591муковисцидозингаляционный тобрамицинсинегнойная палочкаReferencesDöring G., Conway S.P., Heijerman H.G.M. et al. Antibiotic therapy against Psudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000; 16: 749-767.Döring G., Conway S.P., Heijerman H.G.M. et al. Antibiotic therapy against Psudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000; 16: 749-767.Толстова В.Д., Каширская Н.Ю., Капранов Н.И. Массовый скрининг на муковисцидоз в России. Фарматека 2008; 1: 38-43.Толстова В.Д., Каширская Н.Ю., Капранов Н.И. Массовый скрининг на муковисцидоз в России. Фарматека 2008; 1: 38-43.Zielenski J., Rozmahel R., Bozon D. et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10: 214-228.Zielenski J., Rozmahel R., Bozon D. et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10: 214-228.Milla C.E. Nutrition and lung disease in cystic fibrosis. Clin. Chest Med. 2007; 28: 319-330.Milla C.E. Nutrition and lung disease in cystic fibrosis. Clin. Chest Med. 2007; 28: 319-330.Cystic Foundation Patient Registry. 2005 annual data report. Maryland; 2006.Cystic Foundation Patient Registry. 2005 annual data report. Maryland; 2006.Cystic Foundation Patient Registry. 1996 annual data report. Maryland; 2006.Cystic Foundation Patient Registry. 1996 annual data report. Maryland; 2006.Gibson R.L., Emerson J., McNamara S. et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 841-849.Gibson R.L., Emerson J., McNamara S. et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 841-849.Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994; 34: 255-259.Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994; 34: 255-259.Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-226.Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219-226.Knowles M.R., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588-2595.Knowles M.R., Robinson J.M., Wood R.E. et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588-2595.Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740-1746.Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740-1746.Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs 2007; 9: 11-20.Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs 2007; 9: 11-20.Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658-664.Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658-664.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23-30.Chuchalin A., Gyurkovics K., Bartnicka M.T. et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr. Drugs 2007; 9: 21-31.Chuchalin A., Gyurkovics K., Bartnicka M.T. et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr. Drugs 2007; 9: 21-31.Kerem E., Reisman J., Corey M. et al. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 1992; 326: 1187-1191.Kerem E., Reisman J., Corey M. et al. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 1992; 326: 1187-1191.Ramsey B.W., Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J. Pediatr. 1994; 124: 177-192.Ramsey B.W., Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J. Pediatr. 1994; 124: 177-192.Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120: 107S-113S.Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120: 107S-113S.Marostica P.J., Weist A.D., Eigen H. et al. Spirometry in 3- to 6-year-old children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 67-71.Marostica P.J., Weist A.D., Eigen H. et al. Spirometry in 3- to 6-year-old children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 67-71.Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55-63.Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55-63.Anderson G.G., Moreau-Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. and Immun. 2008; 76: 1423-1433.Anderson G.G., Moreau-Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. and Immun. 2008; 76: 1423-1433.Burns J.L., Van Dalfsen J.M., Shawar R.M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 1999; 179: 1190-1196.Burns J.L., Van Dalfsen J.M., Shawar R.M. et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 1999; 179: 1190-1196.Murphy T.D., Anbar R.D., Lester L.A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 2004; 38: 314-320.Murphy T.D., Anbar R.D., Lester L.A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 2004; 38: 314-320.Iles R., Legh-Smith J., Drummond M. et al. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J. Cyst. Fibros. 2003; 2: 120-128.Iles R., Legh-Smith J., Drummond M. et al. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J. Cyst. Fibros. 2003; 2: 120-128.Weiner J.R., Toy E.L., Sacco P., Duh M.S. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert. Opin. Pharmacother. 2008; 9: 751-766.Weiner J.R., Toy E.L., Sacco P., Duh M.S. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert. Opin. Pharmacother. 2008; 9: 751-766.Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol. 2002; 33: 269-276.Quittner A.L., Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol. 2002; 33: 269-276.Hill D.M., Fukushima L.K., Hsu E., Woo M.S. Obstacles to use of high-dose aerosolized tobramycin in eligible cystic fibrosis patients. In: American Thoracic Society Conference, 2005.Hill D.M., Fukushima L.K., Hsu E., Woo M.S. Obstacles to use of high-dose aerosolized tobramycin in eligible cystic fibrosis patients. In: American Thoracic Society Conference, 2005.LeLorier J., Perreault S., Birnbaum H. et al. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin. Ther. 2000; 22: 140-151.LeLorier J., Perreault S., Birnbaum H. et al. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin. Ther. 2000; 22: 140-151.Courtney J.M., Bradley J., Mccaughan J. et al. Predictors of mortality in adults with cystic fibrosis. Pediatr. Pulmonol. 2007; 42: 525-532.Courtney J.M., Bradley J., Mccaughan J. et al. Predictors of mortality in adults with cystic fibrosis. Pediatr. Pulmonol. 2007; 42: 525-532.Stern M., Wiedemann B., Wenzlaff P. The German CFQA Group from registry to quality management: The German CF Quality Assessment project 1995-2006. Eur. Respir. J. 2008; 31: 29-35.Stern M., Wiedemann B., Wenzlaff P. The German CFQA Group from registry to quality management: The German CF Quality Assessment project 1995-2006. Eur. Respir. J. 2008; 31: 29-35.Lamb H.M., Goa K.L. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis. Manage Hlth Outcomes 1999; 6: 93-108.Lamb H.M., Goa K.L. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis. Manage Hlth Outcomes 1999; 6: 93-108.Nikolaizik W.H., Trociewicz K., Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur. Respir. J. 2002; 20: 122-126.Nikolaizik W.H., Trociewicz K., Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur. Respir. J. 2002; 20: 122-126.Ramagopal M., Lands L.C. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr. Pulmonol. 2000; 29: 366-370.Ramagopal M., Lands L.C. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr. Pulmonol. 2000; 29: 366-370.AHFS drug information 2006. Tobramycin sulfate. http://www.ashp.org/ahfs/first_rel/Revised-tobramycin_oct2006.pdf [accessed 1 Nov 2007]AHFS drug information 2006. Tobramycin sulfate. http://www.ashp.org/ahfs/first_rel/Revised-tobramycin_oct2006.pdf [accessed 1 Nov 2007]Modi A.C., Quittner A.L. Barriers to treatment adherence for children with cystic fibrosis and asthma: What gets in the way? J. Pediatr. Psychol. 2006; 31: 846-858.Modi A.C., Quittner A.L. Barriers to treatment adherence for children with cystic fibrosis and asthma: What gets in the way? J. Pediatr. Psychol. 2006; 31: 846-858.Modi A.C., Lim C.S., Yu N. et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J. Cyst. Fibros. 2006 5: 177-185.Modi A.C., Lim C.S., Yu N. et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J. Cyst. Fibros. 2006 5: 177-185.Kerem E. Early intervention in CF: When to start treatment and how to measure response? Cyst. Fibros. Worldwide Newslett. 2006; 8 (2): 10-14.Kerem E. Early intervention in CF: When to start treatment and how to measure response? Cyst. Fibros. Worldwide Newslett. 2006; 8 (2): 10-14.Капранов Н.И., Каширская Н.Ю., Радионович А.М. и др. Клиническое значение специальной аэрозольной формы тобрамицина в лечении хронического бронхолeгочного процесса у больных муковисцидозом. Пульмонология 2008; 3: 20-26.Капранов Н.И., Каширская Н.Ю., Радионович А.М. и др. Клиническое значение специальной аэрозольной формы тобрамицина в лечении хронического бронхолeгочного процесса у больных муковисцидозом. Пульмонология 2008; 3: 20-26.Poli G., Acerbi D., Pennini R. et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Pediatr. Drugs 2007; 9: 3-9.Poli G., Acerbi D., Pennini R. et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Pediatr. Drugs 2007; 9: 3-9.Schneiders A.M., Pechtold O., Sommerer K. et al. In vitro characterization of BRAMITOB (inhaled tobramycin 300mg / 4ml) with next generation nebulisers. Congress of the Italian Cystic Fibrosis Society, 2007.Schneiders A.M., Pechtold O., Sommerer K. et al. In vitro characterization of BRAMITOB (inhaled tobramycin 300mg / 4ml) with next generation nebulisers. Congress of the Italian Cystic Fibrosis Society, 2007.Hubert D., Leroy S., Dominique S., Kovarik J. Pharmacokinetic comparison of inhaled tobramycin (TOBI) via PARI eFlow rapid or PARI LC PIusTM nebulizers in cystic fibrosis patients. J. Cyst. Fibros. 2007; 6 (Suppl. 1): S12 (abstract A050 and poster).Hubert D., Leroy S., Dominique S., Kovarik J. Pharmacokinetic comparison of inhaled tobramycin (TOBI) via PARI eFlow rapid or PARI LC PIusTM nebulizers in cystic fibrosis patients. J. Cyst. Fibros. 2007; 6 (Suppl. 1): S12 (abstract A050 and poster).
The authors declare that there are no conflicts of interest present.